Patient P-02216

Synthetic patientMETA-24 · Day 172 · 55–64 · F · baseline S11Steering view · 3D Open companion preview

Therapy response

Improving

Tolerance

Favorable

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Improving

Discontinuation risk

51%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S11
Day 69 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 74 GI-04 recommended — GI Support Protocol GI-04
Day 75 Patient accepted — Started GI-04 in the companion
Day 80 ME-01 recommended — Monitoring Escalation ME-01
Day 81 Patient accepted — Started ME-01 in the companion
Day 83 GI symptom burden −36% vs expected — GI Support Protocol GI-04
Day 84 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 89 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 69.

Primary contributors, last 14 days

Inflammatory activity-7
Nutritional resilience+6
GI instability-5
Treatment adherence+3
Toxicity-3

What helped?

GI Support Protocol GI-04Day 74
Result: symptom burden −36%
Monitoring Escalation ME-01Day 80
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dietary Support Protocol NP-02

54%

probability of meaningful tolerance improvement

284 similar trajectories
64% showed improvement
median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

33 min

worsening · -2.1 vs previous 14 d

Sleep duration

Wearable

6.8 h

stable · -0.0 vs previous 14 d

Energy level

Daily log

4.1/10

worsening · -1.1 vs previous 14 d

Steps

Wearable

2,948

worsening · -219 vs previous 14 d

GI burden

Companion

47.5/100

worsening · +10.0 vs previous 14 d

Adherence

Companion

50.4 %

stable · +1.5 vs previous 14 d

Sleep quality

Wearable

30.9/100

worsening · -3.5 vs previous 14 d

Glucose, CGM daily mean

CGM

144 mg/dL

stable · +4.8 vs previous 14 d

This trajectory is doing well — what to keep, what to watch

Steering view →

Heading towards restoration · 44 from the failing basin, 44 from restoration.

Good elements to keep

GI Support Protocol GI-04
intervention · steering +49
Protein (supports)
perturbation · steering +8.3
Monitoring Escalation ME-01
intervention · steering +4.3
Protein
supporter · GI -5 next day

Main detractors to watch

Low butyrate capacity
hidden · steering -17.5
Poor metabolizer
hidden · steering -12.7
Dietary fat load
perturbation · steering -12.6
Histamine load
perturbation · steering -11
Dietary fat load
detractor · GI +6.1 next day
Histamine load
detractor · GI +6.1 next day

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+6.1detractor · 95%
Histamine load
+6.1detractor · 95%
Caffeine
+5.3detractor · 95%
Simple carbohydrates
+5.2detractor · 95%
Protein
-5supporter · 95%
Alcohol
+4.6detractor · 95%
Ultra-processed food
+3.9detractor · 95%
Insoluble fibre
-2.3no signal · 53%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 48 and rising
Inflammatory signalling ↓60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 43
- WearableHRV 24 ms, trending down
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 36/100
- Daily logFibre intake low in recent food logs
Autonomic recovery ↑45
- WearableResting HR 84 bpm
- Wearable2,948 steps/day
Drug metabolism and exposure ↑40
- DNACYP2D6 poor metabolizer → higher exposure

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Poor metabolizer
Higher exposure at standard dose
GLP1R rs6923761 A
Altered receptor sensitivity

Microbiome

Shannon diversity 2.4 · butyrate capacity 36/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 25 ms
Sleep: 6.5 h
Steps: 3,521
Resting HR: 84 bpm

Daily log: GI score 48, nutritional resilience 48, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02410	39%	S01	GI-04	improved	55
P-02018	37%	S01	GI-04	improved	46
P-02054	35%	S01	CR-01	improved	57
P-02409	33%	S01	SC-12	no change	54
P-02307	28%	S01	—	—	55
P-02598	27%	S01	—	—	53
P-02276	26%	S01	—	—	57
P-02550	26%	S01	—	—	70
P-02568	26%	S01	—	—	51
P-02041	24%	S01	—	—	27
P-02087	24%	S01	BR-03	no change	40
P-02437	24%	S01	—	—	64